Letermovir in End-Stage Kidney Disease With or Without Dialysis
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how a single dose of letermovir (an antiviral pill) is processed by the body in people with end-stage kidney disease, whether or not they are on dialysis. It helps doctors understand dosing for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have end-stage kidney disease (very low kidney function).
- You are either on regular dialysis or not on dialysis (both groups are needed).
- You are willing to take a single dose of letermovir and have blood drawn through a small tube (cannula).
- You are not taking certain medications that could interfere with the study drug (a full list will be provided).
- If you could become pregnant, you agree to use effective birth control for 30 days after the dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
This study tests a drug called letermovir to prevent CMV infection after a kidney or liver transplant. It is for adults at moderate risk of CMV and may help keep you healthy after surgery.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
Hear when a new End-Stage Kidney Disease (ESKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.